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We empirically evaluated the performance of a new method for age adjustment of cancer survival compared to traditional age
adjustment using data from the Finnish Cancer Registry. We find that both methods provide almost identical results for absolute
survival but the new method generally provides more meaningful estimates of relative survival with often a smaller standard error.
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Five or 10-year are commonly reported outcome measures by
cancer registries. Because prognosis strongly depends on age for
many forms of cancer, age adjustment is often employed in
comparative analyses such as international comparative survival
studies. However, traditional age adjustment, which is based on
calculating a weighted average of age-specific survival with weights
reflecting the age distribution of cancer patients in some (typically
site-specific) standard cancer population (Verdecchia et al, 1999),
is often hindered by sparseness of data within certain age groups.
Furthermore, it has been shown that traditional age adjustment
may substantially shift relative survival rates downward even if the
standard population has the same age distribution as the study
population (Brenner and Hakulinen, 2003).
Recently, an alternative method of age adjustment has been
proposed to overcome both the practical difficulties and the
conceptual inconsistencies in age adjustment of survival (Brenner
et al, 2004). In this paper, we provide a comparative empirical
assessment of point estimates of absolute and relative survival
rates and their standard errors obtained with the traditional and
the alternative methods.
MATERIALS AND METHODS
Our analysis is based on data from the Finnish Cancer Registry,
which covers the whole population of Finland (about 5.3 million
people) and is well recognised for its high data quality and
completeness (Teppo et al, 1994). Our empirical analysis was
carried out among patients aged 15 years or older who were
diagnosed with one of 15 common forms of cancer in 1989 and
followed with respect to vital status until the end of 1999. The site-
specific EUROCARE-2 cancer populations, reflecting the age
distribution of patients diagnosed in 1985–1989 and included in
the comparative analyses of cancer survival in Europe within the
EUROCARE-2 project (Berrino et al, 1999), were used as standard
populations for age adjustment.
We first carried out descriptive analyses of the age distribution
of the Finnish cancer patients and the EUROCARE-2 standard
cancer populations. We then calculated age-specific absolute and
relative survival rates for each cancer site. Relative survival rates
were calculated as the absolute survival rates divided by the
expected survival rates in the absence of cancer (Ederer et al,
1961). The latter were derived from age-, sex- and calendar year-
specific life tables of the general Finnish population using
Hakulinen’s (1982) method.
Next, we calculated crude and age-adjusted absolute and relative
survival rates and their standard errors. Age adjustment to the
EUROCARE-2 standard cancer populations was performed both by
the traditional method and by the alternative method recently
proposed by Brenner et al (2004). With the former method, a
weighted average of age-specific survival rates is calculated,
whereas with the latter method, age-specific weights are individu-
ally assigned to patients in the first place, and one then carries out
conventional survival analysis using the weighted individual data.
As in the EUROCARE project, the following five age groups were
used for age adjustment with both methods: 15–44, 45–54, 55–64,
65–74 and 75þ years. For prostate cancer, which is extremely rare
among younger and middle-aged adults, the age groups were 15–
54, 55–64, 65–74, 75–84, and 85þ years. The usual formula
(based on large sample approximations) for the standard error of
traditionally adjusted survival rates often cannot be applied due to
lack of data within single age strata (Verdecchia et al, 1999). Also
available formulae may often substantially overestimate standard
errors of relative survival rates (Brenner and Hakulinen,
2005). Formulae for straightforward estimates of the standard
error of the alternatively adjusted survival rates are yet to be
developed for these reasons, standard errors of all types of survival
rates were determined empirically by bootstrap analysis as the
standard deviation of the respective point estimates in 10000
bootstrap samples for each cancer site (Efron and Tibshirani,
1986).
All analyses were performed with publicly available SAS macros
for both absolute and relative survival analysis (Arndt et al, 2004;
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yBrenner et al, 2004), which were extended to allow for bootstrap
analyses.
RESULTS
Table 1 shows the numbers and age distribution of patients
included in this analysis by cancer site. The most frequent cancer
in Finland in 1989 was breast cancer, followed by lung, prostate,
stomach and colon cancers. The age distribution strongly varied by
cancer site. Relatively high proportions of patients with thyroid
and cervical cancer and melanoma were below age 45 years,
whereas almost half of the patients with prostate cancer were 75
years or older at the time of diagnosis. For most cancers, the age
distribution of Finnish patients was not too different from the age
distribution of the EUROCARE standard population. For some
cancers (cancers of the oral cavity, cervix and corpus uteri),
however, the proportion of older patients was much higher in
Finland, which underlines the importance of age adjustment if
survival comparisons are made even within Europe.
As Table 2 shows, a strong age gradient with lower rates among
older than among younger patients was seen for both absolute and
relative survival for most forms of cancer. The age gradient was
particularly large for patients with cancers of the uterine cervix,
the ovaries, the urinary bladder and the thyroid gland. No clear age
gradient was seen for relative survival of patients with stomach and
breast cancers, and relative survival was higher in the oldest than
in the youngest age group in prostate cancer.
The crude and age-adjusted absolute survival rates and their
standard errors are given in Table 3. Both the point estimates and
their standard errors were virtually identical for both methods of
age adjustment. Adjusted point estimates were quite similar to the
Table 1 Numbers and age distribution of patients diagnosed with common forms of cancer above 14 years of age in Finland in 1989 who were included
in the analysis (the age distribution of patients in the EUROCARE-2 standard population is given for comparison)
Cancer patients in Finland 1989 EUROCARE-2 standard population
Proportion (%) in age group Proportion (%) in age group
Cancer site N 15–44 years 75+ years 15–44 years 75+ years
Oral cavity 416 8.9 32.7 8.8 18.1
Stomach 1039 4.3 41.3 3.3 39.2
Colon 970 6.3 41.8 3.6 39.6
Rectum 599 4.0 36.2 3.4 35.0
Pancreas 651 4.2 39.2 2.7 37.3
Lung 1909 2.0 25.5 2.1 25.5
Breast 2549 12.9 22.8 13.9 21.3
Cervix 159 20.1 32.1 36.6 11.1
Corpus 576 2.6 28.8 4.0 20.0




Kidneys 571 5.6 26.4 5.9 23.0
Urinary bladder 650 2.9 39.1 2.8 34.6
Melanoma 474 26.2 19.6 29.9 14.7
Thyroid gland 268 37.7 14.9 34.9 14.8
aProportion in the age group 15–54 years.
Table 2 Five- and 10-year absolute and relative survival of patients diagnosed with common forms of cancer at ages 15–44 and 75+ years in Finland in
1989
Absolute Relative
5 year-survival 10-year-survival 5 year-survival 10-year-survival
15–44 75+ 15–44 75+ 15–44 75+ 15–44 75+
Oral cavity 73.0 33.1 73.0 8.8 73.8 60.2 74.9 35.7
Stomach 23.0 9.6 23.0 5.6 23.3 17.3 23.7 22.3
Colon 77.0 27.7 72.1 15.1 77.7 47.7 73.6 54.6
Rectum 66.7 19.8 58.3 9.2 67.4 34.9 59.9 35.0
Pancreas 14.8 0.0 11.1 0.0 15.0 0.0 11.5 0.0
Lung 21.1 2.3 15.8 0.2 21.4 4.0 16.4 0.8
Breast 80.1 47.9 68.4 19.7 80.7 77.2 69.6 62.3
Cervix 81.3 15.7 81.3 7.8 81.8 25.6 82.5 26.0
Corpus 86.7 34.9 86.7 19.3 87.3 54.6 88.3 57.4
Ovaries 75.0 15.9 72.5 5.3 75.4 25.6 73.6 16.7
Prostate
a 41.2 20.4 17.6 2.9 43.0 69.7 19.6 56.3
Kidneys 81.3 25.8 78.1 10.6 82.5 42.9 81.0 36.3
Urinary bladder 94.7 28.3 94.7 7.9 96.3 52.2 98.4 33.3
Melanoma 87.9 41.9 83.0 18.3 88.8 69.7 85.0 61.1
Thyroid gland 98.0 25.0 98.0 10.0 98.6 40.2 99.5 32.3
aAge classes are 15–54 and 85+ years.
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ycrude ones for those cancer sites with a similar age distribution in
Finland and the EUROCARE population. Age-adjusted 5- and 10-
year absolute survival rates were considerably higher than the
crude ones for those cancers with a higher proportion of younger
patients in the standard population and a strong age gradient in
prognosis (cancers of the oral cavity, cervix and corpus uteri).
The crude and age-adjusted relative survival rates and their
standard errors are given in Table 4. Unlike the age-adjusted
absolute survival rates, they often differed according to the method
of age adjustment. The differences were mostly modest for 5-year
relative survival estimates, but substantial differences were seen for
some of the 10-year relative survival estimates (point estimates up
to 6.7% units lower, standard errors up to 1.1% units or, in relative
terms, 40% higher with the traditional method compared to the
alternative method). With traditional age adjustment, the adjusted
10-year relative survival estimates were quite close to or lower than
the crude estimates, even when the age distribution was shifted
towards the younger ages as, for example, in oral cavity and
bladder cancers. In other cases (e.g. thyroid cancer), traditional
age adjustment substantially reduced 10-year relative survival
Table 3 Crude and age-adjusted 5- and 10-year absolute survival of patients diagnosed with common forms of cancer above 14 years of age in Finland in
1989
5-year absolute survival 10-year absolute survival
Age adjusted Age adjusted
PE s.e. PE s.e.
Cancer site Crude T A T A Crude T A T A
Oral cavity 48.5 51.7 51.7 2.64 2.65 33.3 38.6 38.6 2.53 2.53
Stomach 17.1 17.3 17.3 1.16 1.17 13.0 13.2 13.1 1.03 1.03
Colon 40.2 39.7 39.7 1.55 1.54 29.9 29.4 29.4 1.42 1.41
Rectum 34.9 35.3 35.2 1.90 1.92 24.7 25.2 25.2 1.69 1.72
Pancreas 1.4 1.3 1.3 0.44 0.44 1.1 1.0 1.0 0.41 0.40
Lung 7.9 8.1 8.1 0.62 0.63 4.5 4.6 4.6 0.48 0.48
Breast 71.2 71.3 71.4 0.86 0.85 54.2 54.5 54.4 0.91 0.92
Cervix 49.0 62.6 62.6 3.99 3.99 42.1 57.2 57.3 3.95 3.92
Corpus 62.8 67.5 67.5 1.78 1.80 51.4 56.8 56.8 1.88 1.91
Ovaries 32.3 34.6 34.6 2.16 2.17 24.3 26.7 26.7 1.94 1.97
Prostate 42.6 42.8 42.8 1.36 1.35 19.1 19.1 19.1 1.06 1.06
Kidneys 44.8 46.3 46.3 2.02 2.02 32.6 34.3 34.3 1.88 1.88
Urinary bladder 49.2 50.6 50.6 1.82 1.85 31.6 33.2 33.2 1.66 1.67
Melanoma 71.3 73.5 73.4 1.88 1.90 59.0 62.1 62.0 2.03 2.04
Thyroid gland 77.2 74.9 75.0 2.26 2.23 72.8 70.4 70.4 2.25 2.21
Age adjustment is made to the site-specific EUROCARE-2 standard population. Point estimates (PE) and their standard errors (s.e.) obtained by bootstrap analyses with 10000
replications are given for age adjustment by the traditional method (T) and by the alternative method (A).
Table 4 Crude and age-adjusted 5- and 10-year relative survival of patients diagnosed with common forms of cancer above 14 years of age in Finland in
1989
5-year relative survival 10-year relative survival
Age adjusted Age adjusted
PE s.e. PE s.e.
Cancer site Crude T A T A Crude T A T A
Oral cavity 61.5 61.2 61.1 3.04 3.13 54.5 52.9 54.8 3.59 3.58
Stomach 22.8 22.0 22.9 1.52 1.54 23.7 23.3 23.7 2.13 1.84
Colon 52.3 51.0 51.4 2.07 1.97 52.1 52.0 50.9 2.97 2.41
Rectum 45.0 43.9 45.1 2.49 2.46 42.4 40.9 42.6 3.29 2.89
Pancreas 1.8 1.4 1.7 0.47 0.56 1.9 1.2 1.8 0.46 0.69
Lung 10.0 9.5 10.2 0.75 0.79 7.5 6.3 7.6 0.68 0.79
Breast 80.8 80.6 80.7 1.05 0.95 70.8 69.6 70.6 1.47 1.18
Cervix 57.6 65.4 67.4 4.17 4.28 59.0 62.9 67.0 4.47 4.57
Corpus 73.7 75.0 76.5 2.06 2.03 73.0 72.6 74.8 2.71 2.49
Ovaries 37.3 37.9 39.1 2.42 2.45 33.0 31.6 34.7 2.52 2.56
Prostate 62.9 64.1 63.4 2.23 1.99 44.5 44.7 44.8 3.55 2.47
Kidneys 54.6 54.3 55.3 2.44 2.40 50.0 48.4 50.6 2.99 2.76
Urinary bladder 66.1 64.8 66.7 2.52 2.41 59.0 53.0 59.7 3.27 2.94
Melanoma 81.4 81.5 82.2 2.19 2.09 77.8 77.0 78.5 3.05 2.55
Thyroid gland 84.5 80.0 82.7 2.74 2.41 87.9 80.7 86.7 3.58 2.67
Age adjustment is made to the site-specific EUROCARE-2 standard population. Point estimates (PE) and their standard errors (s.e.) obtained by bootstrap analyses with 10000
replications are given for age adjustment by the traditional method (T) and by the alternative method (A).
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yestimates, despite very similar age distributions of cancer patients
in the standard population and in the study population. No such
patterns were seen with alternative age adjustment. In addition,
standard errors of age-adjusted relative survival were often
substantially lower with the alternative age adjustment than with
the traditional age adjustment, particularly for 10-year relative
survival.
DISCUSSION
In our previous work, the alternative method for age adjustment
had been empirically illustrated for point estimates of relative
survival for one single cancer site only (Brenner et al, 2004). The
present analysis extends these findings to both point estimates and
their standard errors of both absolute and relative survival rates,
and their relevance is shown for many of the commonest cancers.
In contrast to traditional age adjustment, the alternative method
does not require performance of age-specific analyses, which often
suffer from sparseness of data within age strata. Our analysis
indicates that this conceptually and computationally simple
method essentially provides the same point estimates with the
same standard error as the traditional method for absolute survival
rates (at least in situations where there is little loss to follow-up, as
in the Finnish Cancer Registry), and more meaningful point
estimates with an often smaller standard error for relative survival
rates.
While the often substantially lower standard errors for relative
survival constitute another major advantage of alternative age
adjustment, a straightforward approach for their estimation has
yet to be developed. In the meantime, however, derivation of such
estimates by bootstrap as carried out in this analysis is an easily
implementable alternative. Calculation of standard errors by
bootstrap is to be recommended for relative survival rates anyway
(even for crude analysis and for traditional age adjustment), given
that standard errors of relative survival rates are often substan-
tially overestimated by the conventional approach (Brenner and
Hakulinen, 2005).
The empirical evaluation presented in this paper was restricted
to ‘cohort analysis’ of survival, in which all patients included in the
cohort could have potentially been followed over the full follow-up
period of interest (here, 5 and 10 years), that is, in which there is
no ‘technical censoring’. To explore the implications of technical
censoring, we carried out additional ‘complete analyses’ of 5- and
10-year survival of patients diagnosed in 1989–1999 and followed
until the end of 1999. With this type of analyses, traditional age
adjustment, but not the alternative age adjustment, sometimes also
substantially altered the values of absolute survival estimates, even
when the age distribution of the standard population was the same
as that of the study population. This is due to the fact that both the
observed survival and censoring are age dependent and thus the
censoring is informative. Usual care for informative censoring may
have to be taken with the proposed method as with survival
analysis methods in general.
In summary, application of the alternative method may enhance
both validity and precision of comparative analyses of cancer
survival.
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